ARTICLE | Clinical News
Niaspan niacin-based product regulatory update
November 1, 1999 8:00 AM UTC
The FDA granted marketing approval to Niaspan to increase HDL cholesterol in patients with dyslipidemia. The product is marketd in the U.S. to prevent second heart attacks and to reduce atherosclerosi...